# UTHPEAK NMNH

# The World's First, Largest, and Longest Human Clinical Trial on NMNH

- Product Name: β-Nicotinamide Mononucleotide, reduced form (β-NMNH)
- CAS No.: 4229-56-5

### What is NMNH?

NMNH is the reduced form of Nicotinamide Mononucleotide (NMN). Both NMN and NMNH (reduced NMN) are NAD+ precursors. Research has shown that NMNH is a more effective NAD+ enhancer compared to market available NAD+ precursors.

## ©UTHPEAK® Clinical Study Key Insights

A **90-day** double-blind, placebo-controlled, randomized trial assessing the safety, tolerability, and pharmacokinetics of UthPeak® NMNH with **80 healthy participants**.





NAD+ Levels



**Biological Age** 







**Emotional Health** 







### **Efficacy validation**

The completion of the phase I clinical trial underscores UthPeak®'s potential in anti-aging, anti-fatigue, stress management, safety of UthPeak®. First NMNH with and emotional health improvement.



### Safety

Comprehensive preclinical and human clinical studies to ensure the Self-GRAS status for use in select foods, supplements, & medical foods.



### **Superior stability**

Improved stability designed to be compatible with various product formats.

UthPeak® NMNH 2-8°C Storage

v.s.

Regular NMNH -20°C Storage

### UthPeak® NMNH Clinical Agenda





# **Advantages**



**Patent-pending** 

Stable crystalline form of NMNH



**Purity** 

Purity higher than 98%



Market-ready

First market-ready NMNH product

### UthPeak® Clinical Agenda

The forthcoming UthPeak® clinical trial will assess NMNH's potential in enhancing consumer-centric well-being factors such as sleep quality improvement, cardioprotection, and neuroprotection.



Reference available upon request.

This product has not been evaluated by the Food and Drug Administration This product is not intended to diagnose, treat, cure or prevent any disease











